期

Attorney Docket:

147/50194

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: REGINA SCHOEMAKER

Serial No.: TBA Group Art Unit:

Filed: Herewith Examiner:

Title: USE OF MOXONIDINE FOR POSTMYOCARDIAL

INFARCTION TREATMENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

An English abstract of the European Patent document is submitted herewith, and therefore no concise explanation for such foreign language documents is required.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.



Serial No.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. §1.97(d)(2) and that the petition fee set forth in 37 C.F.R. §1.17(i) in accordance with 37 C.F.R. §1.97(d)(3) should be charged to Deposit Account No. 05-1323 (Docket 147/50194).

Respectfully submitted,

July 31, 2001

--⊅. Evans

Registration No. 26,269

CROWELL & MORING, LLP P.O. Box 14300 Washington, DC 20044-4300

Telephone No.: (202) 628-8800 Facsimile No.: (202) 628-8844